Psychostimulants: Basic and clinical pharmacology

International Review of Neurobiology

Volumn 120, Issue , 2015, Pages 41-83

  McCreary, Andrew C ^a   Müller, Christian P ^b   Filip, Małgorzata ^c,d  

^a CHARLES RIVER LABORATORIES   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

^d JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACAMPROSATE; ACETYLCYSTEINE; AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; BACLOFEN; COCAINE; DEXAMPHETAMINE; DISULFIRAM; DOPAMINE; GABAPENTIN; GALANTAMINE; IMMUNOGLOBULIN G ANTIBODY; KETAMINE; MEMANTINE; METHYLPHENIDATE; MODAFINIL; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; NALTREXONE; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; VACCINE; VARENICLINE; VIGABATRIN; CENTRAL STIMULANT AGENT;

BOREDOM; CLINICAL PHARMACOLOGY; COCAINE DEPENDENCE; COGNITION; COGNITIVE THERAPY; COPING BEHAVIOR; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; EUPHORIA; FATIGUE; HEDONIA; HUMAN; MENTAL PERFORMANCE; MENTAL STRESS; METHAMPHETAMINE DEPENDENCE; MULTICENTER STUDY (TOPIC); NONHUMAN; PERCEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL BEHAVIOR; SOCIAL INTERACTION; SUBSTANCE ABUSE; WELLBEING; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; PROCEDURES; SUBSTANCE-RELATED DISORDERS;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; SUBSTANCE-RELATED DISORDERS;

EID: 84943353116     PISSN: 00747742     EISSN: 21625514     Source Type: Book Series    
DOI: 10.1016/bs.irn.2015.02.008     Document Type: Chapter

References (217)

1. Achat-Mendes, C., Platt, D. M., & Spealman, R. D. (2012). Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics, 343, 214-224.
2. Adamczyk, P., Miszkiel, J., McCreary, A. C., Filip, M., Papp, M., & Przegaliński, E. (2012). The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats. Brain Research, 1444, 45-54.
3. Amen, S. L., Piacentine, L. B., Ahmad, M. E., Li, S. J., Mantsch, J. R., Risinger, R. C., et al. (2011). Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology, 36, 871-878.
4. Anastasio, N. C., Stutz, S. J., Fox, R. G., Sears, R. M., Emeson, R. B., Dileone, R. J., et al. (2014). Functional status of the serotonin 5-HT2C receptor (5-HT2CR) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence. Neuropsychopharmacology, 39, 370-382.
5. Anderson, A. L., Reid, M. S., Li, S. H., Holmes, T., Shemanski, L., Slee, A., et al. (2009). Modafinil for the treatment of cocaine dependence. Drug and Alcohol Dependence, 104, 133-139.
6. Anglin, M. D., Burke, C., Perrochet, B., Stamper, E., & Dawud-Noursi, S. (2000). History of the methamphetamine problem. Journal of Psychoactive Drugs, 32, 137-141.
7. Aronson, S. C., Black, J. E., McDougle, C. J., Scanley, B. E., Jatlow, P., Kosten, T. R., et al. (1995). Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology, 119, 179-185.
8. Arria, A. M., & Wish, E. D. (2006). Nonmedical use of prescription stimulants among students. Pediatric Annals, 35, 565-571.
9. Asevedo, E., Mendes, A. C., Berk, M., & Brietzke, E. (2014). Systematic review of N-acetylcysteine in the treatment of addictions. Revista Brasileira de Psiquiatria, 36, 168-175.
10. Bagasra, O., Forman, L. J., Howeedy, A., & Whittle, P. (1992). A potential vaccine for cocaine abuse prophylaxis. Immunopharmacology, 23, 173-179.
11. Batki, S. L., Washburn, A. M., Delucchi, K., & Jones, R. T. (1996). A controlled trial of fluoxetine in crack cocaine dependence. Drug and Alcohol Dependence, 41, 137-142.
12. Besheer, J., Grondin, J. J., Salling, M. C., Spanos, M., Stevenson, R. A., & Hodge, C. W. (2009). Interoceptive effects of alcohol require mGlu5 receptor activity in the nucleus accumbens. The Journal of Neuroscience, 29, 9582-9591
13. Bespalov, A. Y., Dravolina, O. A., Zvartau, E. E., Beardsley, P. M., & Balster, R. L. (2000). Effects of NMDA receptor antagonists on cocaine-conditioned motor activity in rats. European Journal of Pharmacology, 390, 303-311.
14. Bespalov, A. Y., Zvartau, E. E., Balster, R. L., & Beardsley, P. M. (2000). Effects of N-methyl-D-aspartate receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats. Behavioral Pharmacology, 11, 37-44.
15. Bisaga, A., Aharonovich, E., Cheng, W. Y., Levin, F. R., Mariani, J. J., Raby, W. N., et al. (2010). A placebo-controlled trial of memantine for cocaine dependence with highvalue voucher incentives during a pre-randomization lead-in period. Drug and Alcohol Dependence, 111, 97-104
16. Bisaga, A., Aharonovich, E., Garawi, F., Levin, F. R., Rubin, E., Raby, W. N., et al. (2006). A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug and Alcohol Dependence, 81, 267-274.
17. Boutrel, B., & Koob, G. F. (2004). What keeps us awake: The neuropharmacology of stimulants and wakefulness-promoting medications. Sleep, 27, 1181-1194.
18. Boyd, C. J., McCabe, S. E., Cranford, J. A., & Young, A. (2006). Adolescents' motivations to abuse prescription medications. Pediatrics, 118, 2472-2480.
19. Brensilver, M., Heinzerling, K. G., & Shoptaw, S. (2013). Pharmacotherapy of amphetaminetype stimulant dependence: An update. Drug and Alcohol Review, 32, 449-460.
20. Brensilver, M., Heinzerling, K. G., Swanson, A. N., & Shoptaw, S. J. (2012). A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: Suggested guidelines for treatment discontinuation/augmentation. Drug and Alcohol Dependence, 125, 169-172.
21. Britt, G. C., & McCance-Katz, E. F. (2005). A brief overview of the clinical pharmacology of "club drugs" Substance Use and Misuse, 40, 1189-1201.
22. Broadley, K. J. (2010). The vascular effects of trace amines and amphetamines. Pharmacology & Therapeutics, 125, 363-375.
23. Brodie, J. D., Case, B. G., Figueroa, E., Dewey, S. L., Robinson, J. A., Wanderling, J. A., et al. (2009). Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. The American Journal of Psychiatry, 166, 1269-1277
24. Brodie, J. D., Figueroa, E., & Dewey, S. L. (2003). Treating cocaine addiction: From preclinical to clinical trial experience with gamma-vinyl GABA. Synapse, 50, 261-265.
25. Brodie, J. D., Figueroa, E., Laska, E. M., & Dewey, S. L. (2005). Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse, 55, 122-125.
26. Cami, J., Farré, M., Mas, M., Roset, P. N., Poudevida, S., Mas, A., et al. (2000). Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): Psychomotor performance and subjective effects. Journal of Clinical Psychopharmacology, 20, 455-466.
27. Carroll, K. M., Fenton, L. R., Ball, S. A., Nich, C., Frankforter, T. L., Shi, J., et al. (2004). Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Archives of General Psychiatry, 61, 264-272.
28. Carroll, K. M., Nich, C., Ball, S. A., McCance, E., Frankforter, T. L., & Rounsaville, B. J. (2000). One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: Sustained effects of treatment. Addiction, 95, 1335-1349
29. Castren, E. (2005). Is mood chemistry? Nature Reviews. Neuroscience, 6, 241-246.
30. Chadwick, M. J., Gregory, D. L., & Wendling, G. (1990). A double-blind amino acids, L-tryptophan and L-tyrosine, and placebo study with cocaine-dependent subjects in an inpatient chemical dependency treatment center. The American Journal of Drug and Alcohol Abuse, 16, 275-286.
31. Chick, J. (1999). Can light or moderate drinking benefit mental health? European Addiction Research, 5, 74-81.
32. Coffin, P. O., Santos, G. M., Das, M., Santos, D. M., Huffaker, S., Matheson, T., et al. (2013). Aripiprazole for the treatment of methamphetamine dependence: A randomized, double-blind, placebo-controlled trial. Addiction, 108, 751-761
33. Collins, S. L., Levin, F. R., Foltin, R. W., Kleber, H. D., & Evans, S. M. (2006). Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug and Alcohol Dependence, 82, 158-167.
34. Collins, S., & Surwit, R. S. (2001). The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis. Recent Progress in Hormone Research, 56, 309-328.
35. Collins, E. D., Vosberg, S. K., Ward, A. S., Haney, M., & Foltin, R. W. (2007). The effects of acute pretreatment with high-dose memantine on the cardiovascular and behavioral effects of cocaine in humans. Experimental and Clinical Psychopharmacology, 15, 228-237.
36. Condon, J., & Smith, N. (2003). Prevalence of drug use: Key findings from the 2002/2003 British Crime Survey. Findings, 229, 1-5.
37. Cornish, J. W., Maany, I., Fudala, P. J., Ehrman, R. N., Robbins, S. J., & O'Brien, C. P. (2001). A randomized, double-blind, placebo-controlled study of ritanserin pharmacotherapy for cocaine dependence. Drug and Alcohol Dependence, 61, 183-189
38. Covi, L., Hess, J. M., Kreiter, N. A., & Haertzen, C. A. (1995). Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. The American Journal of Drug and Alcohol Abuse, 21, 327-344.
39. Cunningham, K. A., & Anastasio, N. C. (2014). Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology, 76(Pt B), 460-478.
40. Cunningham, K. A., Fox, R. G., Anastasio, N. C., Bubar, M. J., Stutz, S. J., Moeller, F. G., et al. (2011). Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues. Neuropharmacology, 61, 513-523
41. Dacher, M., & Nugent, F. S. (2011). Opiates and plasticity. Neuropharmacology, 61, 1088-1096.
42. Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005). A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology, 30, 205-211.
43. Dackis, C. A., Kampman, K. M., Lynch, K. G., Plebani, J. G., Pettinati, H. M., Sparkman, T., et al. (2012). A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Journal of Substance Abuse Treatment, 43, 303-312
44. Dean, L. G., Kendal, R. L., Schapiro, S. J., Thierry, B., & Laland, K. N. (2012). Identification of the social and cognitive processes underlying human cumulative culture. Science, 335, 1114-1118.
45. de Bruin, N. M., Kloeze, B. M., & McCreary, A. C. (2011). The 5-HT6 serotonin receptor antagonist SB-271046 attenuates the development and expression of nicotine-induced locomotor sensitisation in Wistar rats. Neuropharmacology, 61, 451-457.
46. de Bruin, N. M., McCreary, A. C., van Loevezijn, A., de Vries, T. J., Venhorst, J., van Drimmelen, M., et al. (2013). A novel highly selective 5-HT6 receptor antagonist attenuates ethanol and nicotine seeking but does not affect inhibitory response control in Wistar rats. Behavioural Brain Research, 236, 157-165.
47. De Vries, T. J., Shaham, Y., Homberg, J. R., Crombag, H., Schuurman, K., Dieben, J., et al. (2001). A cannabinoid mechanism in relapse to cocaine seeking. Nature Medicine, 7, 1151-1154
48. de Wit, H., & Stewart, J. (1981). Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology, 75, 134-143.
49. Di Chiara, G., Tanda, G., Bassareo, V., Pontieri, F., Acquas, E., Fenu, S., et al. (1999). Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine. Annals of the New York Academy of Sciences, 877, 461-485.
50. Ding, C., Bremer, N. M., Smith, T. D., Seitz, P. K., Anastasio, N. C., Cunningham, K. A., et al. (2012). Exploration of synthetic approaches and pharmacological evaluation of PNU-69176E and its stereoisomer as 5-HT2C receptor allosteric modulators. ACS Chemical Neuroscience, 3, 538-545
51. Dutta, A., McKie, S., & Deakin, J. F. (2014). Ketamine and other potential glutamate antidepressants. Psychiatry Research, 225, 1-13. http://dx.doi.org/10.1016/j.psychres.2014.10.028.
52. Ehrman, R. N., Robbins, S. J., Cornish, J. W., Childress, A. R., & O'Brien, C. P. (1996). Failure of ritanserin to block cocaine cue reactivity in humans. Drug and Alcohol Dependence, 42, 167-174.
53. Eickenhorst, P., Vitzthum, K., Klapp, B. F., Groneberg, D., & Mache, S. (2012). Neuroenhancement among German university students: Motives, expectations, and relationship with psychoactive lifestyle drugs. Journal of Psychoactive Drugs, 44, 418-427.
54. Elkashef, A., Fudala, P. J., Gorgon, L., Li, S. H., Kahn, R., Chiang, N., et al. (2006). Doubleblind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug and Alcohol Dependence, 85, 191-197.
55. Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S. H., Holmes, T., Smith, E. V., et al. (2008). Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology, 33, 1162-1170
56. EMCDDA (2012). European monitoring center for addictive drugs, state of the drug problem 2012. http://www.emcdda.europa.eu/publications/annual-report/2012.
57. Emley, G. S., & Hutchinson, R. R. (1983). Unique influences of 10 drugs upon post-shock biting attack and preshock manual responding. Pharmacology, Biochemistry, and Behavior, 19, 5-12.
58. Engel, J. A., & Jerlhag, E. (2014). Role of appetite-regulating peptides in the pathophysiology of addiction: Implications for pharmacotherapy. CNS Drugs, 28, 875-886.
59. Ersche, K. D., Roiser, J. P., Abbott, S., Craig, K. J., Müller, U., Suckling, J., et al. (2011). Response perseveration in stimulant dependence is associated with striatal dysfunction and can be ameliorated by a D(2/3) receptor agonist. Biological Psychiatry, 70, 754-762.
60. Ferguson, S. M., Mitchell, E. S., & Neumaier, J. F. (2008). Increased expression of 5-HT6 receptors in the nucleus accumbens blocks the rewarding but not psychomotor activating properties of cocaine. Biological Psychiatry, 63, 207-213.
61. Fijal, K., Pachuta, A., McCreary, A. C., Wydra, K., Nowak, E., Papp, M., et al. (2010). Effects of serotonin (5-HT)6 receptor ligands on responding for cocaine reward and seeking in rats. Pharmacological Reports, 62, 1005-1014.
62. Filip, M., Alenina, N., Bader, M., & Przegalinski, E. (2010). Behavioral evidence for the significance of serotoninergic (5-HT) receptors in cocaine addiction. Addiction Biology, 15, 227-249.
63. Filip, M., & Frankowska, M. (2008). GABA(B) receptors in drug addiction. Pharmacological Reports, 60, 755-770.
64. Filip, M., Frankowska, M., Sadakierska-Chudy, A., Suder, A., Szumiec, L., Mierzejewski, P., et al. (2015). GABA receptors as a therapeutic strategy in substance use disorders: Focus on positive allosteric modulators. Neuropharmacology, 88, 36-47.
65. Filip, M., Golda, A., Zaniewska, M., McCreary, A. C., Nowak, E., Kolasiewicz, W., et al. (2006). Involvement of cannabinoid CB1 receptors in drug addiction: Effects of rimonabant on behavioral responses induced by cocaine. Pharmacological Reports, 58, 806-819
66. Fischman, M. W., & Schuster, C. R. (1980). Cocaine effects in sleep-deprived humans. Psychopharmacology, 72, 1-8.
67. Foley, K. F. (2005). Mechanism of action and therapeutic uses of psychostimulants. Clinical Laboratory Science, 18, 107-113.
68. Forray, A., & Sofuoglu, M. (2014). Future pharmacological treatments for substance use disorders. British Journal of Clinical Pharmacology, 77, 382-400.
69. Fossberg, E., Beisland, H. O., & Lundgren, R. A. (1983). Stress incontinence in females: Treatment with phenylpropanolamine. A urodynamic and pharmacological evaluation. Urologia Internationalis, 38, 293-299.
70. Frankowska, M., Jastrzebska, J., Nowak, E., Bialko, M., Przegaliński, E., & Filip, M. (2014). The effects of N-acetylcysteine on cocaine reward and seeking behaviors in a rat model of depression. Behavioural Brain Research, 266, 108-118.
71. Freeman, K. B., Heal, D. J., McCreary, A. C., & Woolverton, W. L. (2012). Assessment of ropinirole as a reinforcer in rhesus monkeys. Drug and Alcohol Dependence, 125, 173-177.
72. Gawin, F., Riordan, C., & Kleber, H. (1985). Methylphenidate treatment of cocaine abusers without attention deficit disorder: A negative report. The American Journal of Drug and Alcohol Abuse, 11, 193-197.
73. Gonzalez, G., Desai, R., Sofuoglu, M., Poling, J., Oliveto, A., Gonsai, K., et al. (2007). Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug and Alcohol Dependence, 87, 1-9.
74. Grabowski, J., Rhoades, H., Elk, R., Schmitz, J., Davis, C., Creson, D., et al. (1995). Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: Two placebo-controlled double-blind trials. Journal of Clinical Psychopharmacology, 15, 163-174.
75. Grabowski, J., Rhoades, H., Stotts, A., Cowan, K., Kopecky, C., Dougherty, A., et al. (2004). Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: Two double-blind randomized clinical trials. Neuropsychopharmacology, 29, 969-981
76. Grabowski, J., Roache, J. D., Schmitz, J. M., Rhoades, H., Creson, D., & Korszun, A. (1997). Replacement medication for cocaine dependence: Methylphenidate. Journal of Clinical Psychopharmacology, 17, 485-488
77. Grassi, M. C., Cioce, A. M., Giudici, F. D., Antonilli, L., & Nencini, P. (2007). Shortterm efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: A pilot study. Pharmacological Research, 55, 117-121.
78. Grinspoon, L., & Hedblom, P. (2005). A historical overview of amphetamines. In N. Harris (Ed.), Amphetamines (pp. 19-30). Detroit: Thomson Gale.
79. Hagen, E. H., Sullivan, R. J., Schmidt, R., Morris, G., Kempter, R., & Hammerstein, P. (2009). Ecology and neurobiology of toxin avoidance and the paradox of drug reward. Neuroscience, 160, 69-84.
80. Halberstadt, A. L., & Nichols, D. E. (2010). Serotonin and serotonin receptors in hallucinogen action. In C. P.Müller & B. L. Jacobs (Eds.), Handbook of the behavioral neurobiology of serotonin (pp. 621-636). London: Academic Press.
81. Haney, M., Hart, C. L., & Foltin, R. W. (2006). Effects of baclofen on cocaine selfadministration: Opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology, 31, 1814-1821.
82. Hassan, Z., Muzaimi, M., Navaratnam, V., Yusoff, N. H., Suhaimi, F. W., Vadivelu, R., et al. (2013). From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neuroscience and Biobehavioral Reviews, 37, 138-151
83. Heilig, M., & Koob, G. F. (2007). A key role for corticotropin-releasing factor in alcohol dependence. Trends in Neurosciences, 30, 399-406.
84. Heinzerling, K. G., Gadzhyan, J., van Oudheusden, H., Rodriguez, F., McCracken, J., & Shoptaw, S. (2013). Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence. The Journal of Adolescent Health, 52, 502-505
85. Heinzerling, K. G., Shoptaw, S., Peck, J. A., Yang, X., Liu, J., Roll, J., et al. (2006). Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 85, 177-184.
86. Heinzerling, K. G., Swanson, A. N., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014). Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction, 109, 1878-1886.
87. Heinzerling, K. G., Swanson, A. N., Kim, S., Cederblom, L., Moe, A., Ling, W., et al. (2010). Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 109, 20-29.
88. Higgins, S. T., Bickel, W. K., Hughes, J. R., Lynn, M., Capeless, M. A., & Fenwick, J. W. (1990). Effects of intranasal cocaine on human learning, performance and physiology. Psychopharmacology, 102, 451-458
89. Hopitt, W., & Laland, K. N. (2013). Social learning. Princeton: Princeton University Press.
90. Howell, L. L., & Cunningham, K. A. (2015). Serotonin 5-HT2 receptor interactions with dopamine function: Implications for therapeutics in cocaine use disorder. Pharmacological Reviews, 67, 176-197.
91. Huffman, M. A. (2003). Animal self-medication and ethno-medicine: Exploration and exploitation of the medicinal properties of plants. The Proceedings of the Nutrition Society, 62, 371-381
92. Hulka, L. M., Eisenegger, C., Preller, K. H., Vonmoos, M., Jenni, D., Bendrick, K., et al. (2014). Altered social and non-social decision-making in recreational and dependent cocaine users. Psychological Medicine, 44, 1015-1028
93. Hyytiä, P., Bäckström, P., & Liljequist, S. (1999). Site-specific NMDA receptor antagonists produce differential effects on cocaine self-administration in rats. European Journal of Pharmacology, 378, 9-16.
94. Javaid, J. I., Fischman, M. W., Schuster, C. R., Dekirmenjian, H., & Davis, J. M. (1978). Cocaine plasma concentration: Relation to physiological and subjective effects in humans. Science, 202, 227-228.
95. Johnson, B. A., Ait-Daoud, N., Elkashef, A. M., Smith, E. V., Kahn, R., Vocci, F., et al. (2008). A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. The International Journal of Neuropsychopharmacology, 11, 1-14
96. Jones, C. A., & McCreary, A. C. (2008). Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology, 55, 1056-1065.
97. Kahn, R., Biswas, K., Childress, A. R., Shoptaw, S., Fudala, P. J., Gorgon, L., et al. (2009). Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug and Alcohol Dependence, 103, 59-64.
98. Kalivas, P. W. (2004). Recent understanding in the mechanisms of addiction. Current Psychiatry Reports, 6, 347-351.
99. Kalix, P., & Braenden, O. (1985). Pharmacological aspects of the chewing of khat leaves. Pharmacological Reviews, 37, 149-164.
100. Kampman, K. M., Dackis, C., Pettinati, H. M., Lynch, K. G., Sparkman, T., & O'Brien, C. P. (2011). A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addictive Behaviors, 36, 217-221
101. Kelley, A. E., Cador, M., & Stinus, L. (1990). Exploration and its measurement. A psychopharmacological perspective. In A. A. Boulton, G. B. Baker, & A. J. Greenshaw (Eds.), Neuromethods 13-Psychopharmacology (pp. 95-143). Clifton, New Jersey: Humana Press.
102. Kerrigan, S., Mott, A., Jatzlau, B., Ortiz, F., Perrella, L., Martin, S., et al. (2014). Designer psychostimulants in urine by liquid chromatography-tandem mass spectrometry. Journal of Forensic Sciences, 59, 175-183.
103. King, A. J., Johnson, D. D., & Van Vugt, M. (2009). The origins and evolution of leadership. Current Biology, 19, R911-R916.
104. Kirkham, T. C., Williams, C. M., Fezza, F., & Di Marzo, V. (2002). Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology, 136, 550-557.
105. Kishi, T., Matsuda, Y., Iwata, N., & Correll, C. U. (2013). Antipsychotics for cocaine or psychostimulant dependence: Systematic review and meta-analysis of randomized, placebo-controlled trials. The Journal of Clinical Psychiatry, 74, e1169-e1180.
106. Koob, G. F., & Le Moal, M. (1997). Drug abuse: Hedonic homeostatic dysregulation. Science, 278, 52-58.
107. Kotlińska, J., & Biala, G. (2000). Memantine and ACPC affect conditioned place preference induced by cocaine in rats. Polish Journal of Pharmacology, 52, 179-185.
108. Landry, M. J. (2002). MDMA: A review of epidemiologic data. Journal of Psychoactive Drugs, 34, 163-169. LaRowe, S. D., Myrick, H., Hedden, S., Mardikian, P., Saladin, M., McRae, A., et al. (2007). Is cocaine desire reduced by N-acetylcysteine? The American Journal of Psychiatry, 164, 1115-1117.
109. Lende, D. H., & Smith, E. O. (2002). Evolution meets biopsychosociality: An analysis of addictive behavior. Addiction, 97, 447-458.
110. Levin, F. R., Evans, S. M., Brooks, D. J., & Garawi, F. (2007). Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug and Alcohol Dependence, 87, 20-29.
111. Li, Y., White, F. J., & Wolf, M. E. (2000). Pharmacological reversal of behavioral and cellular indices of cocaine sensitization in the rat. Psychopharmacology, 151, 175-183.
112. Lile, J. A., Stoops, W. W., Allen, T. S., Glaser, P. E., Hays, L. R., & Rush, C. R. (2004). Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology, 171, 441-449.
113. Lile, J. A., Stoops, W. W., Glaser, P. E., Hays, L. R., & Rush, C. R. (2004). Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug and Alcohol Dependence, 76, 81-91.
114. Liu, S., Lane, S. D., Schmitz, J. M., Cunningham, K. A., John, V. P., & Moeller, F. G. (2013). Effects of escitalopram on attentional bias to cocaine-related stimuli and inhibitory control in cocaine-dependent subjects. Journal of Psychopharmacology, 27, 801-807.
115. Longo, M., Wickes, W., Smout, M., Harrison, S., Cahill, S., & White, J. M. (2010). Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction, 105, 146-154.
116. Marcuse, L. (1984). Philosophie des Gluecks (2nd ed.). Zürich: Diogenes.
117. Maremmani, A. G., Pacini, M., Rovai, L., Rugani, F., Dell'osso, L., & Maremmani, I. (2011). Can ropinirole modulate reinforcing subjective effects of cocaine in humans? Frontiers in Psychology, 2, 50.
118. Margolin, A., Kosten, T. R., Avants, S. K., Wilkins, J., Ling, W., Beckson, M., et al. (1995). A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug and Alcohol Dependence, 40, 125-131.
119. Martell, B. A., Mitchell, E., Poling, J., Gonsai, K., & Kosten, T. R. (2005). Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry, 58, 158-164.
120. Martell, B. A., Orson, F. M., Poling, J., Mitchell, E., Rossen, R. D., Gardner, T., et al. (2009). Cocaine vaccine for the treatment of cocaine dependence in methadonemaintained patients: A randomized, double-blind, placebo-controlled efficacy trial. Archives of General Psychiatry, 66, 1116-1123
121. Martinez-Raga, J., Knecht, C., & Cepeda, S. (2008). Modafinil: A useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies. Current Drug Abuse Reviews, 1, 213-221.
122. McCabe, S. E., Knight, J. R., Teter, C. J., & Wechsler, H. (2005). Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction, 100, 96-106.
123. McClure, E. A., Gipson, C. D., Malcolm, R. J., Kalivas, P. W., & Gray, K. M. (2014). Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs, 28, 95-106.
124. McCreary, A. C., & Jones, C. A. (2010). Antipsychotic medication: The potential role of 5-HT(1A) receptor agonism. Current Pharmaceutical Design, 16, 516-521.
125. McElhiney, M. C., Rabkin, J. G., Rabkin, R., & Nunes, E. V. (2009). Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: A pilot study. The American Journal of Drug and Alcohol Abuse, 35, 34-37.
126. Meini, M., Moncini, M., Cecconi, D., Cellesi, V., Biasci, L., Simoni, G., et al. (2012). Aripiprazole and ropinirole treatment for cocaine dependence: Evidence from a pilot study. Current Pharmaceutical Design, 17, 1376-1383.
127. Miles, S. W., Sheridan, J., Russell, B., Kydd, R., Wheeler, A., Walters, C., et al. (2013). Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: A randomized, double-blind, placebo-controlled trial. Addiction, 108, 1279-1286.
128. Mitchell, E. S., & Neumaier, J. F. (2005). 5-HT6 receptors: A novel target for cognitive enhancement. Pharmacology & Therapeutics, 108, 320-333.
129. Moeller, F. G., Schmitz, J. M., Steinberg, J. L., Green, C. M., Reist, C., Lai, L. Y., et al. (2007). Citalopram combined with behavioral therapy reduces cocaine use: A doubleblind, placebo-controlled trial. The American Journal of Drug and Alcohol Abuse, 33, 367-378
130. Morgan, C. J., Noronha, L. A., Muetzelfeldt, M., Fielding, A., & Curran, H. V. (2013). Harms and benefits associated with psychoactive drugs: Findings of an international survey of active drug users. Journal of Psychopharmacology, 27, 497-506.
131. Müller, C. P. (2015). Eyes on the price: Human culture and its teaching. The Behavioral and Brain Sciences. (in press).
132. Müller, C. P., & Homberg, J. R. (2015). The role of serotonin in drug use and addiction. Behavioural Brain Research, 277, 146-192.
133. Müller, C. P., & Jacobs, B. L. (2010). Handbook of the behavioral neurobiology of serotonin. London: Academic Press.
134. Müller, C. P., Lenz, B., & Kornhuber, J. (2012). Gene-independent heritability of behavioural traits: Don't we also need to rethink the "environment"? The Behavioral and Brain Sciences, 35, 374-375.
135. Müller, C. P., Pum, M. E., Amato, D., Schuttler, J., Huston, J. P., & Silva, M. A. (2011). The in vivo neurochemistry of the brain during general anesthesia. Journal of Neurochemistry, 119, 419-446.
136. Müller, C. P., & Schumann, G. (2011a). Drugs as instruments: A new framework for nonaddictive psychoactive drug use. The Behavioral and Brain Sciences, 34, 293-310.
137. Müller, C. P., & Schumann, G. (2011b). To use or not to use: Expanding the view on non-addictive psychoactive drug consumption and its implications. The Behavioral and Brain Sciences, 34, 328-347.
138. Nich, C., McCance-Katz, E. F., Petrakis, I. L., Cubells, J. F., Rounsaville, B. J., & Carroll, K. M. (2004). Sex differences in cocaine-dependent individuals' response to disulfiram treatment. Addictive Behaviors, 29, 1123-1128.
139. Nichols, D. E. (2004). Hallucinogen. Pharmacology & Therapeutics, 101, 131-181.
140. O'Malley, P. M., & Johnston, L. D. (2002). Epidemiology of alcohol and other drug use among American college students. Journal of Studies on Alcohol. Supplement, 14, 23-39.
141. Oliveto, A., McCance-Katz, F. E., Singha, A., Petrakis, I., Hameedi, F., & Kosten, T. R. (2001). Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. Drug and Alcohol Dependence, 63, 155-167
142. Oliveto, A., Poling, J., Mancino, M. J., Feldman, Z., Cubells, J. F., Pruzinsky, R., et al. (2011). Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug and Alcohol Dependence, 113, 184-191.
143. Oliveto, A., Poling, J., Mancino, M. J., Williams, D. K., Thostenson, J., Pruzinsky, R., et al. (2012). Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction, 107, 131-141.
144. Orson, F. M., Wang, R., Brimijoin, S., Kinsey, B. M., Singh, R. A., Ramakrishnan, M., et al. (2014). The future potential for cocaine vaccines. Expert Opinion on Biological Therapy, 14, 1271-1283
145. Padwa, H., Ni, Y. M., Barth-Rogers, Y., Arangua, L., Andersen, R., & Gelberg, L. (2014). Barriers to drug use behavior change among primary care patients in urban United States community health centers. Substance Use & Misuse, 49, 743-751.
146. Parran, T. V., Jr., & Jasinski, D. R. (1991). Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Archives of Internal Medicine, 151, 781-783.
147. Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nature Medicine, 13, 1102-1107.
148. Patrick, M. E., & Maggs, J. L. (2008). Short-term changes in plans to drink and importance of positive and negative alcohol consequences. Journal of Adolescence, 31, 307-321.
149. Perez-Mana, C., Castells, X., Torrens, M., Capella, D., & Farre, M. (2013). Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database of Systematic Reviews, 9, CD009695.
150. Perez-Mana, C., Castells, X., Vidal, X., Casas, M., & Capella, D. (2011). Efficacy of indirect dopamine agonists for psychostimulant dependence: A systematic review and meta-analysis of randomized controlled trials. Journal of Substance Abuse Treatment, 40, 109-122.
151. Peroutka, S. J., Newman, H., & Harris, H. (1988). Subjective effects of 3,4- methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology, 1, 273-277.
152. Petrakis, I. L., Carroll, K. M., Nich, C., Gordon, L. T., McCance-Katz, E. F., Frankforter, T., et al. (2000). Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction, 95, 219-228.
153. Pettinati, H. M., Kampman, K. M., Lynch, K. G., Xie, H., Dackis, C., Rabinowitz, A. R., et al. (2008). A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addictive Behaviors, 33, 651-667.
154. Plebani, J. G., Lynch, K. G., Yu, Q., Pettinati, H. M., O'Brien, C. P., & Kampman, K. M. (2012). Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug and Alcohol Dependence, 121, 163-166.
155. Poling, J., Oliveto, A., Petry, N., Sofuoglu, M., Gonsai, K., Gonzalez, G., et al. (2006). Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Archives of General Psychiatry, 63, 219-228.
156. Poling, J., Rounsaville, B., Gonsai, K., Severino, K., & Sofuoglu, M. (2010). The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: A pilot study. The American Journal on Addictions, 19, 401-408.
157. Pomierny-Chamiolo, L., Rup, K., Pomierny, B., Niedzielska, E., Kalivas, P. W., & Filip, M. (2014). Metabotropic glutamatergic receptors and their ligands in drug addiction. Pharmacology & Therapeutics, 142, 281-305
158. Potenza, M. N., Sofuoglu, M., Carroll, K. M., & Rounsaville, B. J. (2011). Neuroscience of behavioral and pharmacological treatments for addictions. Neuron, 69, 695-712.
159. Preller, K. H., Hulka, L. M., Vonmoos, M., Jenni, D., Baumgartner, M. R., Seifritz, E., et al. (2014). Impaired emotional empathy and related social network deficits in cocaine users. Addiction Biology, 19, 452-466
160. Ramo, D. E., Grov, C., Delucchi, K. L., Kelly, B. C., & Parsons, J. T. (2011). Cocaine use trajectories of club drug-using young adults recruited using time-space sampling. Addictive Behaviors, 36, 1292-1300.
161. Ramsay, R. R., & Hunter, D. J. (2002). Inhibitors alter the spectrum and redox properties of monoamine oxidase A. Biochimica et Biophysica Acta, 1601, 178-184.
162. Resnick, R. B., Kestenbaum, R. S., & Schwartz, L. K. (1977). Acute systemic effects of cocaine in man: A controlled study by intranasal and intravenous routes. Science, 195, 696-698.
163. Riddle, E. L., Topham, M. K., Haycock, J. W., Hanson, G. R., & Fleckenstein, A. E. (2002). Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. European Journal of Pharmacology, 449, 71-74.
164. Rodriguez, E., & Wrangham, R. (1993). Zoopharmacognosy: The use of medicinal plants by animals. Recent Advances in Phytochemistry, 27, 89-105.
165. Rothman, R. B. (1990). High affinity dopamine reuptake inhibitors as potential cocaine antagonists: A strategy for drug development. Life Sciences, 46, L17-L21.
166. Sabioni, P., Ramos, A. C., & Galduroz, J. C. (2013). The effectiveness of treatments for cocaine dependence in schizophrenic patients: A systematic review. Current Neuropharmacology, 11, 484-490.
167. SAMHSA (2011) National survey on drug use and health, Substance Abuse and Mental Health Services Administration, Rockville. http://www.samhsa.gov/data/NSDUH/ 2011SummNatFindDetTables/Index.aspx.
168. Sarter, M., Hasselmo, M. E., Bruno, J. P., & Givens, B. (2005). Unraveling the attentional functions of cortical cholinergic inputs: Interactions between signal-driven and cognitive modulation of signal detection. Brain Research Reviews, 48, 98-111.
169. Satel, S. L., Krystal, J. H., Delgado, P. L., Kosten, T. R., & Charney, D. S. (1995). Tryptophan depletion and attenuation of cue-induced craving for cocaine. The American Journal of Psychiatry, 152, 778-783.
170. Schmitz, J. M., Green, C. E., Stotts, A. L., Lindsay, J. A., Rathnayaka, N. S., Grabowski, J., et al. (2014). A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: Modafinil, levodopa-carbidopa, naltrexone. Drug and Alcohol Dependence, 136, 100-107.
171. Schmitz, J. M., Mooney, M. E., Moeller, F. G., Stotts, A. L., Green, C., & Grabowski, J. (2008). Levodopa pharmacotherapy for cocaine dependence: Choosing the optimal behavioral therapy platform. Drug and Alcohol Dependence, 94, 142-150.
172. Schmitz, J. M., Stotts, A. L., Sayre, S. L., DeLaune, K. A., & Grabowski, J. (2004). Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. The American Journal on Addictions, 13, 333-341.
173. Schoffelmeer, A. N., Vanderschuren, L. J., De Vries, T. J., Hogenboom, F., Wardeh, G., & Mulder, A. H. (2000). Synergistically interacting dopamine. D1 and NMDA receptors mediate nonvesicular transporter-dependent GABA release from rat striatal medium spiny neurons. The Journal of Neuroscience, 20, 3496-3503.
174. Schubiner, H., Saules, K. K., Arfken, C. L., Johanson, C. E., Schuster, C. R., Lockhart, N., et al. (2002). Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology, 10, 286-294.
175. See, R. E. (2005). Neural substrates of cocaine-cue associations that trigger relapse. European Journal of Pharmacology, 526, 140-146.
176. Sesack, S. R., & Pickel, V. M. (1990). In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Research, 527, 266-279.
177. Shearer, J., Darke, S., Rodgers, C., Slade, T., van Beek, I., Lewis, J., et al. (2009). A doubleblind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction, 104, 224-233.
178. Shearer, J., Wodak, A., Mattick, R. P., van Beek, I., Lewis, J., Hall, W., et al. (2001). Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction, 96, 1289-1296.
179. Shearer, J., Wodak, A., van Beek, I., Mattick, R. P., & Lewis, J. (2003). Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction, 98, 1137-1141.
180. Shippenberg, T. S., & Koob, G. F. (2002). Recent advances in animal models of drug addiction and alcoholism. In K. L. Davis, D. Charney, J. T. Coyle, & C. Nemeroff (Eds.), Neuropsychopharmacology: The fifth generation of progress (pp. 1381-1397). Philadelphia, PA: Lippincott Williams and Wilkins.
181. Shoptaw, S., Heinzerling, K. G., Rotheram-Fuller, E., Steward, T., Wang, J., Swanson, A. N., et al. (2008). Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 96, 222-232.
182. Shoptaw, S., Huber, A., Peck, J., Yang, X., Liu, J., Jeff, D., et al. (2006). Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 85, 12-18.
183. Shoptaw, S., Yang, X., Rotheram-Fuller, E. J., Hsieh, Y. C., Kintaudi, P. C., Charuvastra, V. C., et al. (2003). Randomized placebo-controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. The Journal of Clinical Psychiatry, 64, 1440-1448
184. Singh, D.,Müller, C. P., & Vicknasingam, B. K. (2014). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 139, 132-137.
185. Sitte, H. H., Huck, S., Reither, H., Boehm, S., Singer, E. A., & Pifl, C. (1998). Carriermediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. Journal of Neurochemistry, 71, 1289-1297.
186. Skogen, J. C., Harvey, S. B., Henderson, M., Stordal, E., & Mykletun, A. (2009). Anxiety and depression among abstainers and low-level alcohol consumers. The Nord-Trondelag Health Study. Addiction, 104, 1519-1529.
187. Skrinska, V. A., & Gock, S. B. (2005). Measurement of 3,4-MDMA and related amines in diagnostic and forensic laboratories. Clinical Laboratory Science, 18, 119-123.
188. Smirnov, A., Najman, J. M., Hayatbakhsh, R., Plotnikova, M., Wells, H., Legosz, M., et al. (2013). Young adults' trajectories of Ecstasy use: A population based study. Addictive Behaviors, 38, 2667-2674
189. Sofuoglu, M., & Carroll, K. M. (2011). Effects of galantamine on cocaine use in chronic cocaine users. The American Journal on Addictions, 20, 302-303.
190. Sofuoglu, M., Waters, A. J., Poling, J., & Carroll, K. M. (2011). Galantamine improves sustained attention in chronic cocaine users. Experimental and Clinical Psychopharmacology, 19, 11-19.
191. Spanagel, R., & Kiefer, F. (2008). Drugs for relapse prevention of alcoholism: Ten years of progress. Trends in Pharmacological Sciences, 29, 109-115.
192. Spanagel, R., Vengeliene, V., Jandeleit, B., Fischer, W. N., Grindstaff, K., Zhang, X., et al. (2014). Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology, 39, 783-791
193. Stillman, R., Jones, R. T., Moore, D., Walker, J., & Welm, S. (1993). Improved performance 4 hours after cocaine. Psychopharmacology, 110, 415-420.
194. Stolerman, I. (1992). Drugs of abuse: Behavioural principles, methods and terms. Trends in Pharmacological Sciences, 13, 170-176.
195. Sulzer, D. (2011). How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron, 69, 628-649.
196. Swendsen, J., Burstein, M., Case, B., Conway, K. P., Dierker, L., He, J., et al. (2012). Use and abuse of alcohol and illicit drugs in US adolescents: Results of the National Comorbidity Survey-Adolescent Supplement. Archives of General Psychiatry, 69, 390-398.
197. Tatarkiewicz, W. (1976). Analysis of happiness (p. 356). The Hague, Martinus Nijhoff.
198. Thiel, C. M., Müller, C. P., Huston, J. P., & Schwarting, R. K. (1999). High versus low reactivity to a novel environment: Behavioural, pharmacological and neurochemical assessments. Neuroscience, 93, 243-251.
199. Tiihonen, J., Krupitsky, E., Verbitskaya, E., Blokhina, E., Mamontova, O., Fohr, J., et al. (2012). Naltrexone implant for the treatment of polydrug dependence: A randomized controlled trial. The American Journal of Psychiatry, 169, 531-536.
200. Tiihonen, J., Kuoppasalmi, K., Fohr, J., Tuomola, P., Kuikanmaki, O., Vorma, H., et al. (2007). A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. The American Journal of Psychiatry, 164, 160-162
201. Tzschentke, T. M., & Schmidt, W. J. (2003). Glutamatergic mechanisms in addiction. Molecular Psychiatry, 8, 373-382.
202. Uosukainen, H., Tacke, U., & Winstock, A. R. (2014). Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users. International Journal of Drug Policy, 26, 78-83.
203. van Gaalen, M. M., Schetters, D., Schoffelmeer, A. N., & De Vries, T. J. (2010). 5-HT6 antagonism attenuates cue-induced relapse to cocaine seeking without affecting cocaine reinforcement. The International Journal of Neuropsychopharmacology, 13, 961-965.
204. Volkow, N. D., Fowler, J. S., & Wang, G. J. (2003). Positron emission tomography and single-photon emission computed tomography in substance abuse research. Seminars in Nuclear Medicine, 33, 114-128.
205. Wagner, F. A., & Anthony, J. C. (2002). From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology, 26, 479-488.
206. Waldorf, D., Reinarman, C., & Murphy, S. (1991). Cocaine changes: The experience of using and quitting. Philadelphia: Temple University Press.
207. Weil, A. (1998). The natural mind: A new way of looking at drugs and the higher consciousness. Boston, MA, USA: Houghton Mifflin.
208. Weintraub, D., Masek, M., & Billingham, M. E. (1985). The lymphocyte subpopulations in cyclosporine-treated human heart rejection. The Journal of Heart Transplantation, 4, 213-216.
209. Westfall, T. C. (2006). Neuropeptide Y and sympathetic control of vascular tone in hypertension. EXS, 95, 89-103.
210. White, N. M. (1996). Addictive drugs as reinforcers: Multiple partial actions on memory systems. Addiction, 91, 921-949.
211. Winhusen, T. M., Kropp, F., Lindblad, R., Douaihy, A., Haynes, L., Hodgkins, C., et al. (2014). Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. The Journal of Clinical Psychiatry, 75, 757-764
212. Winhusen, T., Somoza, E., Singal, B. M., Harrer, J., Apparaju, S., Mezinskis, J., et al. (2006). Methylphenidate and cocaine: A placebo-controlled drug interaction study. Pharmacology, Biochemistry, and Behavior, 85, 29-38.
213. Winstanley, E. L., Bigelow, G. E., Silverman, K., Johnson, R. E., & Strain, E. C. (2011). A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. Journal of Substance Abuse Treatment, 40, 255-264.
214. Zinberg, N. E. (1984). Drug, set, and setting: The basis for controlled intoxicant use. New Haven: Yale University Press.
215. Zinberg, N. E., & Jacobson, R. C. (1976). The natural history of "chipping" The American Journal of Psychiatry, 133, 37-40.
216. Zorick, T., Sugar, C. A., Hellemann, G., Shoptaw, S., & London, E. D. (2011). Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. Drug and Alcohol Dependence, 118, 500-503.
217. Zuckerman, M. (1990). The psychophysiology of sensation seeking. Journal of Personality, 58, 313-345.